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An expert panel was convened to evaluate the U.S. Environmental Protection Agency’s “Proposed Guidelines for Carcinogen
Risk Assessment” through their application to data sets for chloroform (CHCl 3) and dichloroacetic acid (DCA). The panel also
commented on perceived strengths and limitations encountered in
applying the guidelines to these specific compounds. This latter
aspect of the panel’s activities is the focus of this perspective. The
panel was very enthusiastic about the evolution of these proposed
guidelines, which represent a major step forward from earlier EPA
guidance on cancer-risk assessment. These new guidelines provide
the latitude to consider diverse scientific data and allow considerable flexibility in dose-response assessments, depending on the
chemical’s mode of action. They serve as a very useful template for
incorporating state-of-the-art science into carcinogen risk assessments. In addition, the new guidelines promote harmonization of
methodologies for cancer- and noncancer-risk assessments. While
new guidance on the qualitative decisions ensuing from the determination of mode of action is relatively straightforward, the description of the quantitative implementation of various risk-assessment options requires additional development. Specific areas
needing clarification include: (1) the decision criteria for judging
the adequacy of the weight of evidence for any particular mode of
action; (2) the role of mode of action in guiding development of
toxicokinetic, biologically based or case-specific models; (3) the
manner in which mode of action and other technical considerations provide guidance on margin-of-exposure calculations; (4)
the relative roles of the risk manager versus the risk assessor in
evaluating the margin of exposure; and (5 ) the influence of mode
of action in harmonizing cancer and noncancer risk assessment
methodologies. These points are elaborated as recommendations
The opinions expressed herein are those of the Expert Panel members and do
not necessarily reflect the views of their respective affiliations or the sponsoring organizations.
1
To whom correspondence should be addressed at ILSI Health and Environmental Sciences Institute, 1126 Sixteenth Street, NW, Washington, DC
20036-4804. Fax: (202) 659-3617. E-mail: drobinson@ilsi.org.

for improvements to any revisions. In general, the incorporation of
examples of quantitative assessments for specific chemicals would
strengthen the guidelines. Clearly, any revisions should retain the
emphasis present in these draft guidelines on flexibility in the use
of scientific information with individual compounds, while simultaneously improving the description of the processes by which
these mode-of-action data are organized and interpreted.
Key Words: chloroform; dichloroacetic acid; proposed cancer
guidelines, U.S. EPA; mode of action; margin of exposure; harmonization; modeling, toxicokinetic; evidence, preponderance of;
risk assessment.

In April 1996, the U.S. Environmental Protection Agency
(EPA) published a set of “Proposed Guidelines for Carcinogen
Risk Assessment” (U.S. EPA, 1996), the first revision since the
original guidelines in 1986 (U.S. EPA, 1986). The proposed
guidelines were developed as part of an interoffice program by
a technical panel of the Risk Assessment Forum within EPA’s
Office of Research and Development. The proposed guidelines
take into consideration the complexities of the carcinogenic
process and the rapid pace of ongoing research in carcinogenesis. They acknowledge that insights gained from this research
should be used to make more scientifically based assessments
of the carcinogenic potential of chemical and physical agents
with an emphasis on using mode-of-action information to
project dose-response relationships. Although it is important
that these guidelines remain general and flexible, it is anticipated that supplemental technical guidance documents will be
developed when necessary. Following publication of the proposed guidelines in the Federal Register in April 1996, EPA
requested public comments. The agency also expressed interest
in developing chemical-specific case studies to illustrate and
assess the strengths and limitations of the proposed guidance.
In September of 1996, an expert panel was convened by the
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Health and Environmental Sciences Institute (HESI) of the
International Life Sciences Institute (ILSI) to develop two case
studies related to the application of the EPA’s revised cancerrisk-assessment guidelines (ILSI, 1997). The two compounds
evaluated by this panel were chloroform (CHCl 3) and dichloroacetic acid (DCA). These compounds were selected because
there are significant sources of human exposure. Both occur as
by-products of water chlorination and have been used or suggested for use as markers of the occurrence of trihalomethanes
(THMs) and haloacetic acids (HAAs) in water supplies. Drinking water is the major route of exposure for the public to these
compounds. Occupational exposures do occur with CHCl 3
which is also present at low concentrations in the atmosphere
from a variety of natural and anthropogenic sources (IPCS,
1994). DCA is a metabolite of several chlorinated organic
solvents and has been used as an anti-diabetic drug and for the
treatment of lactic acidosis (IARC, 1995).
There were three major objectives in convening the panel:
● To review the available data relevant to an assessment of
the carcinogenicity of CHCl 3 and DCA, including bioassay
data, information on mutagenicity, metabolism, toxicokinetics,
target organ toxicity, and modes of carcinogenic action.
● To apply the guidance provided in the “Proposed Guidelines for Carcinogen Risk Assessment” (U.S. EPA, 1996) and
to make recommendations regarding appropriate approaches
for assessing the potential carcinogenic risk of these two compounds.
● To provide a critique of the risk assessment process outlined in the “Proposed Guidelines for Carcinogen Risk Assessment” and a commentary on specific issues encountered in
applying the guidelines to CHCl 3 and DCA as case studies.

The activities of the panel were supported by a group of
sponsoring organizations and oversight was provided by a
steering committee (see Acknowledgments). Ten individuals
with expertise in the diverse disciplines required for cancer risk
assessments were nominated for panel membership by the
steering committee. The expertise represented in the group
included the fields of pathology, mutagenesis, carcinogenesis,
hepatic and renal toxicology, pharmacokinetics, and general
risk-assessment. The panel membership did not include epidemiologists because review of the epidemiological data was
considered outside the scope of the charge. These ten experts
and a senior ILSI/HESI staff scientist are the authors of this
perspective.
During the next 12 months, the panel met face-to-face five
times and regularly through conference calling to complete
their report. Following review by four outside experts, the final
report was published in November 1997. For details regarding
the charge to the panel and the specific recommendations for
the two case-study compounds, readers are referred to the
panel’s full report (ILSI, 1997). This article highlights the
expert panel’s experience in applying the guidelines to realworld data sets (point (c) above). In the development of this

TABLE 1
Topics Highlighted in Working with the Proposed Guidelines
Qualitative Considerations Related to Data Base Evaluation
Working with a Diverse Expert Panel
Evaluating Cancer, Noncancer and Intermediate Endpoints
Considering Plausible Modes of Action
Defining the Weight of Evidence
Quantitative Considerations Related to Risk Assessment
Toxicokinetic, Case-Specific and Biologically Based Dose Response
Models
Applying Extrapolation Models from the ‘Point of Departure’
Selection of Appropriate ‘Point of Departure’ for Extrapolation
Use of Quantal vs. Continuous Endpoints for Risk Assessment
Providing a Working Definition of ‘Margin of Exposure
Use of Toxicokinetic Models to Assist in Margin of Exposure Analysis
Risk Management Considerations
Blurring the Distinctions between Risk Assessment and Risk Management
Striving for Consistency in Cancer and Noncancer Risk Assessment
Developing a Library of Case Studies
Consistency of Mode of Action Inferences with Epidemiological Data

critique, the panel has reflected on several questions: What was
learned about the ability to step through a cancer-risk assessment following these guidelines? Do the guidelines strike an
appropriate balance between flexibility and structure? What
important components of the risk assessment process are missing or ambiguously defined in these guidelines? Lastly, what
recommendations might the panel provide for future assessments?
Organization of Topics
The guidelines outline the manner in which broad data sets
on the carcinogenic action of a compound can be organized and
evaluated to produce integrated carcinogenic risk assessments.
These assessments center on developing consensus regarding
the mode or modes of carcinogenic action of specific compounds. The mode of action concept entails a strongly supported, scientific understanding of a plausible sequence of
steps leading from exposure to cancer induction. Once the
mode of action is established, it leads to specific options for
low-dose and interspecies extrapolation. The panel’s deliberations fell into three broad categories (Table I). First, there were
the largely qualitative considerations associated with evaluating data related to each proposed mode of action. Second, there
were semi-quantitative and quantitative considerations into
which the mode of action provides insight: (a) target-tissue
dose metrics, (b) appropriate toxicokinetic and dose-response
models, and (c) the methods for determination of acceptable
exposure levels. Third, several risk management considerations
were noted in relation to differences between these guidelines
and past practices. Each of these specific topics is discussed
separately, followed by a brief summary.
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Qualitative Considerations Related to Database Evaluation
In previous U.S. EPA cancer risk assessments, the single
decision point for proceeding with a quantitative risk assessment was determination of a statistically significant increase in
tumor incidence in an acceptable chronic animal bioassay. The
broader array of biological data were often analyzed only to
assess relevance, i.e., was the response in animals expected in
humans? In general, these other data did not directly influence
the typical quantitative assessment. The default approach consisted of a linearized, multistage (LMS) model with body
weight scaling for interspecies extrapolation, regardless of the
degree of understanding of the mode of action of the carcinogen in question. Incorporation of mode of action at both
qualitative and quantitative levels necessitates a methodical
organization and evaluation of existing data to determine consistency with specific hypotheses. This new approach to the
cancer dose-response assessment process requires a closer interaction than was the case previously among the individuals
from various biological and mathematical disciplines who contribute to cancer risk assessment.
Working with a Diverse Expert Panel. About half of the
ILSI HESI panel consisted of biologically oriented scientists.
These individuals faced the task of explaining their specific
decision-making strategies to other panel members whose
training and experience emphasized a more quantitative approach to cancer risk-assessment problems. The former group
tended to be skeptical of the quantification of cancer risk
assessment. As was the experience of this panel, the breadth of
expertise that should be represented on such expert panels will
foster improved appreciation of the complementary skills required in organizing a mode of action-based argument and then
applying it to quantitative dose-response assessments.
The interdisciplinary composition of the panel was important in the early stages, where individuals reviewed the data
related to their own areas of expertise. At a later stage, the
emphasis on mode of action required a careful evaluation of the
relationship between various non-neoplastic precursor lesions
and cancer for both CHCl 3 and DCA. The panel representation
in toxicology and pathology was especially important for these
evaluations. Individuals with background in pharmacokinetic
modeling aided in integrating the broader data base to show
consistency of responses across dose routes, dosing vehicles,
and animal species. The practical experience of several panel
members in risk assessment was instrumental in translating
qualitative mode of action concepts into integrated, quantitative relationships for the dose response evaluations.
Evaluating Cancer, Noncancer, and Intermediate Endpoints. Evaluation of the available data on the two case-study
chemicals closely followed the order outlined in the guidelines:
“Analysis of Tumor Data,” “Analysis of Other Key Data,” and
“Mode of Action-Related Endpoints,” including “Direct and
Secondary DNA Effects,” “Non-mutagenic and Other Effects,”
and “Identification of Mode(s) of Action.” In the panel’s ex-
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perience, it is essential that these sections be comprehensive
and presented in sufficient detail to serve as a basis for consideration of a range of hypotheses for the mode of action. If a
single, most-plausible mode of action emerges from this analysis, it must be supported by and developed from the broader
discussion.
Evaluation of known or suspected metabolic pathways and
the toxicology of stable metabolites and transient reactive
intermediates must be one of the early steps in identifying and
integrating the relevant data base. Oxidative and reductive
pathways of cytochrome P450-mediated metabolism form reactive intermediates with CHCl 3 that might contribute to carcinogenesis (Pohl et al, 1977; Pohl and Krishna, 1978; Testai
and Vittozzi, 1986; Tomasi et al., 1985; Wolf et al., 1 977).
The consequences of metabolism through these pathways were
evaluated carefully during the panel’s deliberations. In addition, evidence for the mutagenicity of metabolites such as
glyoxalate from DCA (Marnett et al., 1985; Sasaki and Endo,
1978; Sayato et al. 1987; Yamaguchi and Nakagawa, 1993),
free radicals formed by cytochrome P450-mediated CHCl 3
reduction (Pegram et al, 1997; Testai and Vittozzi, 1986;
Tomasi et al., 1985), and glutathione conjugates from CHCl 3
(Green, 1983; Thier et al., 1993) had to be examined, along
with the mutagenicity studies of the parent compound. Comparison with other chemicals with well-established modes of
action can provide important perspective. For instance, experience with CCl 4, which is metabolized solely through a reductive pathway, provided insights for assessing the role of the
reductive pathway in the toxicity, mutagenicity, and carcinogenicity of CHCl 3.
Precursor effects of the chemical on the target organs for
neoplasia, including target tissue toxicity, must be cataloged
and organized. Important considerations in associating such
precursor effects with cancer are the dose-response relationships and establishing whether these other effects are obligatory for or simply incidental to carcinogenesis. Typically, the
information used to evaluate associations of precursor response
with tumors is derived from different studies. Data on intermediate or key precursor events are usually acquired in shorterterm toxicity or mechanistic studies while information on carcinogenicity is obtained in two-year bioassays that may or may
not include interim sacrifices, stop-recovery studies, etc. In
fact, many cancer risk assessments in the past were necessarily
based on bioassays that provided little data other than tumor
incidence. The panel placed emphasis on evaluating the bioassay studies for evidence of association of precursor effects
with tumor formation. If correlations could not be assessed in
these chronic studies, evaluation of precursor effects in subchronic studies employing similar dosing regimens to the
chronic study became the preferred basis for comparison.
To evaluate precursor lesions in the target tissues, pathologists on the panel obtained histopathology slides from the
CHCl 3 cancer bioassay (Jorgenson et al. 1985) and from a
drinking water study on DCA (DeAngelo et al., 1991). With
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CHCl 3, these evaluations were important in establishing that:
(1) cytotoxicity was present at intermediate time points (12 and
18 months) and at the termination of the study, and that (2)
there was a dose-response relationship between drinking water
concentrations of CHCl 3 and kidney toxicity. For DCA, a
careful, retrospective evaluation of the histopathological
changes in the liver was important in reaching the conclusion
that hepatotoxicity occurred at all dose levels used in the
chronic bioassays. All dose levels examined produced toxicity
and were considered to be in excess of a maximally tolerated
dose. Emerging emphasis on mode of action will require retrospective evaluation of the non-tumor lesions in affected
tissues on a more routine basis. This emphasis will likely
necessitate convening pathology review panels to assess archived samples for noncancer endpoints, just as these panels
have been used previously for assessing tumors. In newly
designed bioassays, evaluations of suspected target tissues
should be incorporated at specified intervals during the study,
in all dose groups.
In most cases, the panel reviewed the primary literature on
these compounds to ensure that positions reached were supported and not simply developed from past reviews or evaluations. This activity required a great deal of effort and led to a
certain amount of isolation of experts within their areas of
expertise. Such deliberations could be streamlined by preparation of relevant documentation prior to convening the expert
panel. With the background data organized and summarized,
expert panels could devote more energy to interpretation of the
data for hazard evaluation and dose-response analysis. In our
deliberations, a great deal of the panel’s effort revolved around
organizing the available data and discussing the consistency of
the broad data bases in pointing to specific hypotheses for
modes of carcinogenic action for these two compounds and
their metabolites.
Considering Plausible Modes of Action. Reaching agreement on the mode of action is central to the application of the
proposed cancer guidelines. The panel’s approach to deciding
whether there was a single mode of action or multiple plausible
modes of action was to specify the various possibilities and
evaluate the support for or the evidence against each particular
mode of action. For example, with CHCl 3, potential modes of
action included an obligatory role for cell injury with compensatory hyperplasia as a precursor to carcinogenicity and other
modes of action related to the mutagenic potential of either
reduced free radical metabolites or glutathione conjugates.
These two general modes of action— cytotoxicity and mutagenicity—are not mutually exclusive. They could both occur
simultaneously and contribute differentially at different doses.
In addition, effects may be dose-dependent, i.e., high-dose
effects might not occur at low doses (Counts and Goodman,
1995).
The panel considered data on mutagenicity of CHCl 3, brominated THMs, and CCl 4 in evaluating the genotoxic, DNA-

reactive potential of CHCl 3 and its metabolites. A glutathione
conjugation pathway converts brominated THMs to mutagenic
intermediates in Salmonella transfected with copies of glutathione-S-transferase- (Pegram et al., 1997). However, CHCl 3
is not mutagenic in these bacterial assays and inferences from
the Pegram et al. studies with brominated THMs cannot be
extended to CHCl 3. In addition, comparisons between the hepatotoxicity of CHCl 3 and CCl 4, which is only metabolized by
reductive pathways, indicated that these compounds act on the
liver by different modes of action. The evidence for a role of
mutagenic intermediates in the carcinogenicity of CHCl 3 was
explicitly examined and found to be very weak (Testai et al.,
1990; Testai and Vittozzi, 1986; Tomasi et al., 1985). The
available studies clearly support a dominant role for oxidative
metabolites in the toxicity of CHCl 3 (Ade et al., 1994; De Biasi
et al., 1992; deGroot and Noll 1989; Testai et al., 1990; Testai
and Vittozzi, 1986).
Mode of action is broadly defined in the guidelines. For
instance, they state in one section, “Thus, mode of action
analysis is based on physical, chemical, and biological information that helps to explain critical events in an agent’s influence on development of tumors.” “Critical events” refers to
those biological processes altered by chemical exposure that
influence carcinogenesis. Quantitative dose-response assessments will be more straightforward when the mode of action
also serves to define the active form of the chemical. The mode
of action statement for CHCl 3 would be stated in two parts.
First, CHCl 3 forms oxidized metabolites that cause cell damage
in tissues with high concentrations of the relevant metabolizing
enzyme. Second, metabolite-mediated cytotoxicity leads to cell
death, regenerative hyperplasia, and higher probabilities of cell
mutation and cancer. High rates of compound metabolism and
metabolite-mediated cytotoxicity are thus regarded to be key
steps in CHCl 3 carcinogenicity. Uncertainties in either the
mode of action or in the biologically active agent (i.e., parent
chemical, reactive metabolite, stable, freely circulating metabolite, etc.) would lead to uncertainties in the dose response
assessments and in any subsequent risk estimates.
In establishing a plausible mode of action, a dual approach
should be emphasized. The first part is the articulation of
competing hypotheses and the second part is the evaluation of
evidence for each hypothesis, to determine whether one is
much more plausible than the others. For CHCl 3, the panel
agreed unanimously that a mode of action involving obligatory
cytotoxicity as a precursor to cancer in target tissues was most
plausible, i.e., much more strongly supported by the comprehensive data set than any of the other modes of action. To
paraphrase the conclusion, there should be no significant carcinogenic risk from CHCl 3 at concentrations below those that
cause cell damage. The data on DCA were less informative in
developing clear hypotheses for potential carcinogenic modes
of action, in part because the cancer studies were conducted at
doses that caused overt hepatotoxicity. Although evidence suggested an essential relationship between toxicity, regeneration,
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and carcinogenicity, no single hypothesis for the mode of
action for DCA emerged as the most plausible.
Defining the weight of evidence. A challenge in applying
the mode of action concept to specific data sets occurs in
assessing the adequacy of the weight of evidence for a particular mode of action and in the manner of comparing competing
hypotheses for the mode of action. The guidelines are not
explicit in terms of presentation, organization, and weighting
evidence for competing modes of action. Much of the guidance
addresses factors relevant to interpretation of the adequacy of
investigations of empirical associations, such as epidemiological studies of cancer incidence or mortality and cancer bioassays. Broad criteria for judging the adequacy of weight-ofevidence on mode of action are presented. They include
“mechanistic relevance of the data to carcinogenicity, number
of studies of each endpoint, consistency of results in different
test systems and species, and similar dose-response relationships for tumor and mode of action-related effects.” It is
appropriate for expert panels to evaluate the data supporting
modes of action on a case-by-case basis. Nonetheless, the
determination of the adequacy of the weight of evidence for a
mode of action will be pivotal in characterizing the doseresponse relationship, predicting its shape in the low-dose
region and using this information in the risk assessment for
many compounds. Consideration of a general framework for
assessing the weight of the evidence for a particular mode of
action could serve as an important guide for future efforts,
although the panel did not endorse a rigid set of rules for this
evaluation.
A Workshop on “Issues in Cancer Risk Assessment” was
held in January 1998 in Hanover, Germany. At the workshop,
a framework was proposed to assist in making judgments about
the sufficiency of available data in supporting proposed modes
of carcinogenic action (IPCS, 1998). A well-crafted outline of
the criteria applied in supporting hypotheses for mode of action
will increase transparency in this new risk assessment process.
Some suggestions for considering adequacy of evidence for a
mode of action may also arise from other illustrative case
studies applying these U.S. EPA guidelines (Barton et al.,
1998; Bogdanffy et al., 1999, in press; Conolly et al., 1997,
1998). Inclusion of examples of the weighting of multiple
modes of action would also be helpful in guideline revisions.
Due to the importance of mutagenicity as a potential mode
of action, a generic framework for evaluation of mutagenicity
studies also should be considered. Results of genetic toxicity
studies in a large database, such as that available for CHCl 3,
will inevitably be mixed. The manner in which the weight of
evidence for genotoxicity should be evaluated and presented is
not addressed in the guidelines. For the assessment of the
genotoxicity of CHCl 3 and DCA, the panel used a comprehensive, quantitative weight of evidence approach to evaluate
large, heterogeneous genetic toxicology databases published
by the International Commission for Protection against Envi-
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ronmental Mutagens and Carcinogens—ICPEMC (Lohman et
al., 1992). This evaluation scheme produces a numerical value
that is easily compared. These scores are relative DNA reactivity scores. The maximum positive score is 100 and the
maximum negative score is –100. For over 100 chemicals
evaluated and classified on this basis, the highest positive score
obtained was 49.7 (triazaquone) and the lowest negative score
was –27.7 (ethanol). Other methods of evaluating the preponderance of evidence might also have been chosen.
Results from over 40 studies on CHCl 3 yield a quantitative
net negative score (-14.3), indicating that the weight of evidence supports a non-genotoxic classification (Brusick et al.,
1992; Lohman et al., 1992). The more limited database for
DCA required direct evaluation of the results of individual
studies. The weight of the evidence for the ability of DCA or
its metabolites to induce effects on DNA did not support
assigning a genotoxic mode of carcinogenic action to DCA,
since the bulk of the mutagenicity data were negative or
equivocal (Herbert et al., 1980; DeMarini et al., 1994; Matsuda
et al., 1991; Meier, 1988). The panel noted that capacity of a
particular chemical to cause genotoxicity is dependent on a
variety of factors, e.g., dose/concentration of test material and
the type of test system. The fact that a compound causes
genotoxicity under some limited set of experimental conditions
does not necessarily mean that carcinogenic effects of the
compound would be related to mutagenicity. Ideally, the emphasis on mode of action in these cancer risk assessment
guidelines should impact the nature of future genotoxicity
testing. A weight of evidence evaluation of genotoxicity studies might then place more emphasis on studies conducted in the
target organ of concern than on results from the overall battery
of in vitro and in vivo tests.
Quantitative Risk Assessment Considerations
As described in the guidelines, agreement regarding the
mode of action leads to specific options for dose response
analysis in the range of observation and extrapolation. Dose
response modeling is divided into two components: analysis in
the range of observation and analysis in the range of extrapolation. In the range of observation, whenever data are considered sufficient, the guidelines prefer a biologically based dose
response (BBDR) or case-specific dose-response (CSDR)
model to relate dose to response. Otherwise, as a standard
default procedure, a suite of models is fitted to the response
data and a specific model chosen based on the fit to the data.
The lower 95% confidence limit on a dose associated with an
estimated 10% increased tumor incidence or a 10% increase in
a nontumor response causally related to the carcinogenicity
(LED 10) generally serves as the point of departure for extrapolating the relationship to environmental exposure levels. The
guidelines specify that other points of departure may be more
appropriate for certain data sets and may be used instead of the
LED 10. With CHCl 3, the panel used an ED 10, a central estimate
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of the dose associated with a 10% increase in tumor incidence
(or nontumor precursor response). The panel believes it important to maintain flexibility in the choice of the point of departure on a case-by-case basis. In each case, the choice of a
particular point of departure should be clearly supported in the
body of the assessment.
Extrapolation to lower dose levels, if required, also relies on
a BBDR or CSDR model if such models can be supported by
sufficient data. Otherwise, default approaches are applied in
accordance with the established or presumed mode of action of
the agent. These options include approaches that assume linearity or non-linearity of the dose-response relationship or
others that consider both possibilities. The default approach for
linearity is to extend a straight line to the zero dose/zero
response intercept. This process is a simplification of the
linearized multistage (LMS) modeling recommended in EPA’s
1986 Guidelines for Carcinogen Risk Assessment (U.S. EPA,
1986); the new default has been proposed to avoid a degree of
sophistication associated with the LMS that is unwarranted for
a default. The guidelines indicate that genotoxic compounds
would have a linear dose-response relationship. This assertion
may not necessarily be true and possibilities of non-linear,
genotoxic modes of action as well as linear, non-genotoxic
modes of action have to be considered. These approaches
would have to be supported clearly in the arguments associated
with defining mode of action. Flexibility in the guidelines will
aid in insuring that all pertinent data are carefully considered in
the dose-response assessment.
The default approach recommended by the guidelines for
non-linearity is a margin of exposure (MOE) analysis rather
than a model that attempts to estimate the probability of effects
at low doses. This MOE approach has been introduced to
accommodate cases in which there is sufficient evidence of a
non-linear dose response, but not enough evidence to construct
a mathematical model for the relationship. The MOE is likely
to be the most commonly used method for non-linear modes of
action and needs to be more carefully developed in the guidelines (see III.b. below).
Constructing toxicokinetic, case-specific, and biologically
based dose response models. Toxicokinetic (TK) models are
important in quantitatively organizing available data on absorption, distribution, metabolism, and elimination (Clewell
and Andersen, 1985; Leung, 1991; Page et al., 1997). Thus, TK
modeling is likely to be important in early stages of the
evaluation of the relevant studies. For example, estimates of
tissue dosimetry from different routes of administration may be
required to infer the appropriate target tissue doses associated
with toxicity/carcinogenicity and to help distinguish among
possible modes of action. Although not emphasized in the
proposed guidelines, the range of possible modes of action
should influence the design of the TK, BBDR, or CSDR
models that have a role in the quantitative portions of the risk
assessment. TK models are most useful when the definition of

mode of action specifies the appropriate target tissue dose
metric. The TK model can then be formulated to predict these
tissue doses. In the absence of knowledge of the metric for
tissue dose, TK models can be used to assist in parent chemical
defaults or in making inferences about the active form of the
compound, as done with methylene chloride (Andersen et al.,
1987). For CHCl 3, a likely mode of action was the accumulation of reactive, oxidized metabolites, leading to cell toxicity.
This mode defines the measure of tissue dose, i.e., concentrations of metabolites produced through the oxidative pathway
that will be calculated by the TK model. With DCA, the
absence of a consensus on the mode of action is an impediment
to defining the dose measure that would be estimated by a TK
model with this compound.
In future revisions of the guidelines, it would be helpful to
explicitly emphasize the concept that both a dose metric and a
biological mechanism need to be captured in the mode of
action statement (see Fig. 1). An advantage of a two-part, dose
metric-toxic effect composite definition for the mode of action
is that it aids in defining the defaults and preferred options for
the quantitative risk assessment. The guidelines indicate that
BBDR or CSDR models are preferred; neither is very well
defined. Since both are dose-response models, the dose measure to be incorporated into these models should be specified,
if possible, from the mode of action statement. Mutation rates
or rates of cell division or cell death in the BBDR or CSDR
model can then be related to relevant measures of dose.
CSDR models, by specifying the relevant dose metrics,
would also require the risk assessor to justify the use of the
default dose scaling of bw 0.75 that has become the EPA standard. The two-part definition also more clearly indicates the
role of quantitative models in the risk assessment. Toxicokinetic (TK) models predict tissue dose metrics associated with
a particular mode of action and BBDR models use input from
TK models to predict responses at various exposure levels (Fig.
1). The approach with the CHCl 3 assessment was based on
arguments from the mode of action to support a non-linear
extrapolation and use of a TK model for predicting dose to
tissue, measured as metabolized dose in target tissues. The
tissue doses of CHCl 3 were used as the basis for modeling
tumor outcome. They also serve as the starting point for
extrapolation or for applying adjustment factors as specified in
the guidelines.
The panel extended a physiologically based pharmacokinetic
(PBPK) model for CHCl 3 developed by others (Borghoff et al.,
1994; Corley et al. 1990; Gargas et al., 1990; Lilly, 1996) to
calculate doses of CHCl 3 metabolites in the target tissues, i.e.,
the centrilobular regions of the liver acini and the renal cortex.
These calculated doses of metabolites were correlated with
tissue responses. The panel did not develop a BBDR or CSDR
model for either compound and did not believe it was possible
to construct such a model based on the data available at that
time. Despite the recommendation for the use of BBDR or
CSDR models in the guidelines, there are no examples where
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FIG. 1. Schematic of the qualitative and quantitative aspects of applying mode-of-action considerations
in cancer risk assessment. An optimal
approach consists of unambiguous
characterization of the mode of action and the tissue dose associated
with the toxic responses. In this case
(Path 1), TK models estimate tissue
dose over a range of exposure conditions and provide input into BB-DR
models that predict precursor effect
and tumor incidence from biological
understanding of the processes involved. The process used with CHCl 3
(Path 2) produced estimates based on
measures of tissue dose (see text).

such models have been formally adopted for cancer risk assessment.
Applying extrapolation models from the ‘point of departure’.
Simplification of the linear extrapolation model is welcomed
and should help in more meaningfully informing the risk
management community and the public concerning the lack of
precision in cancer risk estimations that are based frequently on
extrapolation over many orders of magnitude. Nonetheless, the
product of the risk assessment (i.e., excess numbers of cases of
cancer per unit of the population) will likely continue to be
interpreted, particularly by the public, as implying a greater
degree of precision than is warranted. The precision of these
estimates varies from compound to compound. There is greater
confidence in estimation of risk expressed as excess cases of
cancer, when the difference between levels to which the general public is exposed and those that have induced adverse
effects is within an order of magnitude, e.g., arsenic in drinking
water (Clewell et al., 1998). Less confidence would be accorded to risk estimates for compounds that induce adverse
effects in toxicological studies in animals at doses 6 to 7 orders
of magnitude greater than the predicted exposure of humans
(e.g., melamine) (U.S. EPA, 1988) Indeed, in this latter case
there may well be no risk at relevant exposure concentrations.
There is no provision in the current guidelines to reflect these
different degrees of confidence in the database, either in determining the adequacy of the MOE or in pursuing linear
extrapolation from the point of departure.
The proposed
guidelines state that, “The default assumption of linearity is
also appropriate as the ultimate science policy default when
evidence shows no DNA reactivity or other support for linearity but neither does it show sufficient evidence of a non-linear
mode of action to support a non-linear procedure.” Provision of

a single option for these two very different situations, when the
mode of action is clearly consistent with a linear default or
when available data are simply inadequate to support a specific
mode of action, does not reflect the degree of confidence in the
accuracy of the extrapolation. Though controversial, the panel
felt that there should be flexibility to permit adoption of a
non-linear approach (rather than the default assumption of
linearity) for analysis in the range of extrapolation, if the
available data are consistent with non-linearity and inconsistent
with direct genotoxicity, and even though there may be no
clear consensus hypothesis of a specific mode of action. In fact,
the panel’s recommendations following review of the database
on DCA provide such an example.
For DCA, a formal quantitative analysis of the dose response
was not pursued, due to the lack of adequate studies to evaluate
carcinogenicity quantitatively. For instance, the studies in
which DCA-induced tumors appear to have used doses in
excess of current definitions of maximally tolerated doses
(Bucher et al., 1996; Foran, 1997). Because carcinogenicity
was associated with target organ (liver) toxicity (Daniel et al.,
1992; Sanchez and Bull, 1990), overt pharmacological responses and dose-dependent elimination (Cornett et al., 1997;
Gonzalez-Leon and Bull, 1996; Gonzalez-Leon et al, 1997a,b),
a linear approach to extrapolation did not appear to be appropriate for DCA. In addition, pharmacologic studies in humans
at comparably high doses showed no evidence of hepatotoxicity (Stacpoole et al, 1979, 1997). A provisional MOE analysis
was conducted to provide guidance for the prioritization of
further work with DCA. The panel used the no-observedadverse-effect level (NOAEL) for toxicity/carcinogenicity in
the rodent studies (DeAngelo et al, 1991, 1996) and derived a
MOE based on relatively crude estimates of human exposure
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(IARC, 1995; WHO, 1996). The MOE estimated from this
approach (greater than 1300) was considered adequate, based
on the absence of tumors at doses of DCA that do not cause
toxicity, pharmacologic actions, or impaired clearance.
The MOE approach does allow conservatism to be incorporated into the value adopted as the recommended MOE. A
greater margin of exposure would be recommended in cases
with these kinds of mechanistic uncertainties. This option,
recommending an MOE to account for uncertainty in the mode
of action, was preferred over the option currently in the guidelines that advocates adoption of both a linear and non-linear
extrapolation in a case such as that for DCA. The panel
believed that presentation of both approaches, as currently
recommended in the guidelines, provides excessive credibility
to the linear option, which would likely become the preferred
choice for the risk manager. Cancer slope factors derived from
the linear option give estimates of population risks that provide
inappropriate risk-communication information to the public.
The MOE does not provide an analysis as easily abused for
estimating specific population risks.
Selection of the appropriate ‘point of departure’ for extrapolation. After considerable debate about the point of departure
for extrapolation, the panel endorsed latitude in the selection of
points of departure. With rich data sets, an LED 10 utilizes more
of the data and, together with the ED 10, provides an indication
of variability. With sparse data sets, the LED 10 becomes highly
model-dependent and may give a greater impression of accuracy than merited. Depending on the data sets, either an ED 10
or an LED 10 might be preferred for the point of departure, and
there should be flexibility for making this determination on a
case by case basis. However, both central values and upper and
lower confidence limits should always be presented. The panel
strongly endorsed graphical depiction of the point of departure
and confidence bounds. In some cases, use of a NOAEL or
LOAEL might be desirable. The panel’s analyses used a tissue
dose-based ED 10 for CHCl 3 and a NOAEL for DCA. The latter
option was pursued with DCA since the information on doseresponse was not sufficiently robust to establish a point of
departure that offered any advantage over a NOAEL or
LOAEL.
Use of quantal vs. continuous endpoints for risk assessment.
In contrast to previous reliance on analysis of quantal endpoints (i.e., incidence of tumors), analysis of continuous precursor responses will become increasingly important under the
new guidelines. Some issues, such as conversion of continuous
data to quantal data (in the form of the number of animals
showing an ⬙adverse⬙ change in a variable) or definition of
adversity for changes in a continuous variable, such as cell
proliferation for CHCl 3, have not been addressed in the proposed guidelines. Dose response curves for tumor incidence
and those for induced cell proliferation with CHCl 3 were very
similar (Health Canada, 1999). The panel’s tumor-based ED 10
was 71.3 mg CHCl 3 metabolized/liter kidney cortex/h for the

increased incidence of kidney tumors in the Osborne-Mendel
rat. This dose measure was derived from a composite PBPK
model for CHCl 3 disposition (ILSI, 1997). An ED 10/LED 10 for
increased cell proliferation would have been the preferred point
of departure, since cell proliferation, a secondary response
following cytotoxicity, is considered to be an obligatory precursor for cancer. Cell proliferation data were reported as
group means ⫾ SD (Larson et al., 1994a, 1994b, 1995; Templin et al, 1996). Estimating an ED 10 for cell proliferation
requires defining a level of increase in cell proliferation in an
individual animal that would be considered as adverse. Lacking the full data sets, the panel conducted the evaluation based
on tumor incidence.
Providing a working definition of ‘margin of exposure’.
According to the guidelines, an MOE analysis is conducted
when the mode of action dictates a non-linear approach in the
absence of sufficient information for a BBDR or CSDR model.
The MOE is calculated as the ED 10, the LED 10, or another point
of departure divided by the “environmental exposure of interest,” implying, obviously, that exposure data are available. The
adequacy of the calculated MOE should then be evaluated in
light of the uncertainties in both the exposure and the toxicity
estimates. In the guidelines, the definition of “environmental
exposures of interest” is the actual or projected exposures, or
regulatory levels of specific interest with respect to a risk
management requirement. Indeed, exposure and associated exposure-assessment uncertainties have to be considered in their
own right in MOE evaluations. The U.S. EPA’s published
Guidelines for Exposure Assessment and Risk Characterization
Guidance (U.S. EPA, 1992, 1995) provide guidance for these
considerations. Full characterization of exposure of the general population to CHCl 3 and DCA was not within the scope of
the charge to the panel. Exposure was discussed in a cursory
fashion, more as a basis for acquiring experience in developing
MOEs for the specific case studies than for establishing a
precedent for these types of calculations. In this process, several questions became apparent. What criteria are used to
determine representative exposures for the general population,
to compare with calculated points of departure? Are these
estimates media-specific or are they estimates of total exposure? Presumably, the answers vary depending upon the purpose of a particular assessment. Little consideration appears in
the new guidelines regarding close integration of exposure
estimates into the MOE. Confidence in the exposure assessment is an absolutely critical component in determining adequacy of the MOE. A smaller MOE might be acceptable if
estimates of exposure were necessarily based on worst-case
considerations. However, a small MOE would be of considerable concern if estimates of exposure were relatively certain.
The guidelines correctly indicate that characterization of exposure should include a description of the strengths and limitations (uncertainties) of the data and methods. These same
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limitations, related to exposure characterization, should be
factored into evaluating the adequacy of the MOE.
Use of toxicokinetic models to assist in margin of exposure
analysis. TK models can be applied to calculate the tissue
dose associated with a toxic or carcinogenic response. These
models estimate tissue doses at the point of departure in the
animals and at human exposure levels. With CHCl 3, the point
of departure was expressed in terms of the rate of formation of
reactive metabolites per volume target tissue in the liver or
kidney. A target tissue dose using the same metric could also
be calculated for ambient exposures in humans. The ratio
between the tissue dose at the point of departure in the animals
and the tissue dose at ambient human exposure levels becomes
the MOE. This approach was adopted in the panel’s work on
CHCl 3. Alternatively, the tissue dose in animals at the point of
departure could have been converted to an administered dose
equivalent and compared to the human exposure level, a procedure that accounts for animal but not human toxicokinetics.
The procedure based on tissue dose has the advantage of
allowing the evaluation of multiple exposure routes in the
human exposure assessment. The administered-dose approach
could give incorrect estimates for compounds, such as DCA
and CHCl 3, which have dose-dependent pharmacokinetic behavior near the point of departure for the extrapolation.
Risk Management Considerations
Blurring the Distinction between Risk Assessment and Risk
Management
The purpose of an MOE analysis is to provide the risk
manager with all available information on how much reduction
in risk may be associated with reduction in exposure from the
point of departure. This background information supports the
risk manager’s decision of an acceptable MOE for the statute
guiding a particular decision. It is stated that: “A margin of
exposure analysis explains the biological considerations for
comparing the observed data with the environmental exposure
levels of interest and helps in deciding on an acceptable level
of exposure in accordance with applicable management factors.” While this evaluation is considered to fall under risk
management, “the risk assessor is responsible for providing
scientific rationale to support the decision.” Thus, contrary to
previous proposals to clearly delineate risk assessment and risk
management (NRC, 1983, 1994), these new guidelines actually
blur the distinction between them. More responsibility is now
placed in the hands of the risk manager to understand the
uncertainties of the chemical’s database. The risk manager has
to evaluate the adequacy of the MOE against various factors;
almost all of these decisions would be best informed by the risk
assessment.
The guidelines delineate some of the factors that are to be
considered in assessing adequacy of the MOE. They include
the slope of the dose-response curve at the point of departure,
the nature of the response (i.e., precursor lesion, frank toxicity
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or tumors), the nature and extent of human variability, the
persistence of the agent in the body, and the relative speciessensitivity between humans and experimental animals (interspecies variability). If human variability and relative speciessensitivity cannot be estimated from available data, each
should be considered to be at least 10 fold. However, the
guidelines specify that it should not be assumed that “numerical factors are the sole components for determination of an
acceptable margin of exposure.” In the context of these particular factors, the perceived role of the risk manager in determining the adequacy of the MOE is unclear. Indeed, the risk
assessors should address these issues to ensure that the toxicological database is adequately and consistently taken into
account in the development of recommended standards, to
insure protection of public health. For example, most risk
managers are unlikely to be trained to consider the sufficiency
of biological data necessary to replace defaults. Some obvious
factors do fall into the category of risk management, including
sociopolitical aspects related to public perceptions concerning
adversity of particular types of effects.
In practice, the guidelines will result in departure from
current practices. Presently, quantitative risk-management
goals are provided as concentrations or levels considered acceptable by the risk assessor to the risk manager. This change
in procedure will likely create concerns among risk managers
who may be uncomfortable in fulfilling this vaguely defined
new role. While it is not entirely clear how the transfer of these
responsibilities to risk managers will be realized in practice,
the guidelines, at a minimum, necessitate greater interaction
between risk assessors and risk managers. While this discourse
should be beneficial in ensuring that risk assessments are better
tailored to meet the needs of risk management, it will present
a challenge to the integrity of the risk assessment process,
which needs to consider the relevant scientific aspects in determining adequacy of the MOE.
Striving for Consistency in Cancer and Noncancer Risk
Assessment
One of the implications of the proposed guidelines’ emphasis
on mode of action and the potential for use of precursor lesions
(i.e., noncancer endpoints) is the convergence of cancer and
noncancer risk-assessment approaches. For example, where carcinogenicity is secondary to another type of toxicity, the MOE
analysis should be similar to approaches used for these noncancer
responses. The potential to use similar points of departure for dose
response analysis with cancer and noncancer effects also offers
greater opportunity for congruence. Increasing use of the benchmark dose/benchmark concentration in noncancer risk assessment
dovetails with the recommended point of departure for cancer
(i.e., the ED 10 or LED 10). The use of the LED 10 is essentially a
benchmark dose for cancer.
The need for harmonization of cancer and noncancer approaches has been recognized (Barton and Andersen, 1998,
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Conolly, 1995). The cancer risk assessment approach in the
United States differs from that of other countries, where risk
characterization is based on a limiting critical effect, either
cancer or some other endpoint, and determined based on consideration of the entire data set. This approach not only conserves resources, but permits integration across endpoints in
cases where cancer and noncancer effects share common
modes of action. The present practice in the United States with
noncancer endpoints uses a point of departure (BMD, NOAEL,
LOAEL, etc.) and applies dosimetric corrections (U.S. EPA,
1994) and uncertainty factors (UCFs) to derive exposure recommendations that should be without significant public health
consequences. The introduction of these uncertainty factors
occurs in the risk-assessment process itself, and follows well
defined but still evolving procedures (Dourson and Stara, 1983;
Dourson et al, 1992, 1996).
For noncancer assessments, UCFs are selected based on
judgment by experts within the EPA. In general, the factors
used by EPA are intended to account for the specific areas of
uncertainty (Dourson, 1994). The list below recapitulates U.S.
EPA policy. They are described here to show consistencies and
inconsistencies in applying the factors to cancer and noncancer
endpoints.
● Intrahuman: 10-fold when extrapolating from valid experimental results from studies using prolonged exposure to average healthy humans
● Animal to human: For reference doses (RfDs), 10-fold
when extrapolating from valid results of long-term studies on
experimental animals. For reference concentrations (RfCs),
reduced to 3-fold when a NOAEL-human equivalent concentration (HEC) used as basis of estimate.
● Subchronic to chronic: 10-fold when extrapolating from
less than chronic results on experimental animals.
● LOAEL to NOAEL: 10-fold when deriving an RfC or
from a LOAEL instead of a NOAEL
● Incomplete database: 10-fold factor when extrapolating
from valid results in experimental animals when the data are
“incomplete”

Several of these factors may not be relevant for cancer. For
example, the LOAEL to NOAEL extrapolation is not necessary
in most cases since data should be sufficient to derive a
modeled estimate of the point of departure. However, with
compounds such as DCA, for which available data on the dose
response for cancer are exceedingly poor, even a factor of this
kind may be relevant.
An intermediate approach was taken by the panel with
CHCl 3 in which an attempt was made to specify the combination of factors that need to be considered in arriving at a
composite value for the MOE. The ED 10 for tumors was used
as the starting point. A factor of 10 was considered sufficient to
address interindividual variation in determining the adequacy
of the margin of exposure. For interspecies variation, a factor
of 3.1 was considered sufficient, because the starting point is a

measure of tissue dose and PBPK models are available for
estimating tissue doses in exposed humans. An additional
factor to account for severity of effect was considered inappropriate because the dose response curve for tumors closely
paralleled that for the intermediate endpoint. While specific
toxicokinetic calculations of human tissue doses were not
performed by the panel, the acceptable tissue dose (71.3 mg
CHCl 3 metabolized/liter kidney cortex/h divided by the proposed uncertainty factor) would be used with a human PBPK
model to estimate the maximal exposure level. While the panel
did not complete development of a human PBPK model, there
appears to be sufficient data to allow development of such a
model that would incorporate parameters related to the distribution and activity of the CHCl 3-metabolizing CYP2E1 in
human liver and kidney. The approach adopted by the panel for
CHCl 3 may provide a useful example in future revisions of the
guidelines in this regard. However, it is important to emphasize
that, where dosimetric adjustments are made to the point of
departure, this must also be taken into consideration in evaluating the MOE (i.e., a value of less than 10 would be adequate
to address interspecies variability). This implementation of the
interspecies uncertainty considerations, analogous to the interspecies UCF with noncancer endpoints, is consistent with the
approach used in the dosimetry corrections with the RfC calculations (U.S. EPA, 1994).
As the proposed guidelines are applied to a larger number of
compounds, such as the work with vinyl acetate and formaldehyde (Bogdanffy et al., 1999; Conolly et al., 1997, 1998),
more detailed guidance can be developed on the components
necessary for determining the adequacy of MOE values. Cancer risk assessment methodology should be continually updated as experience is gained with noncancer RfD and RfC
evaluations, particularly as noncancer uncertainty factors
evolve from a “presumed protective default” to predictive
values derived from evaluations of relevant toxicity data bases
(Dourson et al., 1996; Renwick, 1993). Revisions to these
guidelines should reflect recent developments in noncancer risk
assessment, contributing to greater consistency between cancer
and noncancer assessments.
Developing a Library of Case Studies
Experience gained from exercises conducted by panels
such as this one and others should help in establishing a case
library to facilitate future improvements of these guidelines.
However, there is a potential drawback to an arrangement
where outside groups bring assessments to the EPA for
comment and concurrence. If agency personnel have not
wrestled with the guidelines and adopted specific approaches for the quantitative assessments, they may be in a
position to criticize efforts of other groups without providing a clear expectation of the contents required in a quantitative assessment under these new guidelines. Therefore, it
would be helpful to the evolution of these guidelines if EPA
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staff also were to conduct several quantitative case studies.
Joint efforts of EPA staff and outside parties could also be
very helpful by bringing diverse perspectives to these case
studies. Such efforts will provide EPA valuable experience
in deciding when a mode of action has sufficient scientific
support and in assessing the appropriate MOE to be used for
specific cases. This panel’s experience emphasizes the value
derived from working with the issues in the guidelines and
carrying specific quantitative examples through the process.
Another valuable lesson from conducting these case studies
is the ability to define more clearly the nature of the data
needs for quantitative mode of action-based risk assessment.
The experience with case studies conducted by multiple
stakeholders should greatly refine our conceptions of the
types of hazard identification and dose-response studies that
provide optimal information for mode of action-based risk
assessment. This experience should be useful in guiding
experimental design and also in guiding EPA and others in
investing in toxicology and dose-response assessment related research.
In the introductory section of the proposed guidelines, under
“Weighting Evidence of Hazard,” the administrator of the U.S.
EPA writes, “In this proposal, decisions come from weighing
all the evidence. This change recognizes the growing sophistication of research methods, particularly in their ability to
reveal modes of action of carcinogenic agents at cellular and
subcellular levels as well as toxicokinetic and metabolic processes. The effect of the change on the assessment of individual agents will depend greatly on the availability of new kinds
of data on them, in keeping up with the state of the art. If these
new data are not forthcoming from public and private research
on agents, assessments under these guidelines will not differ
significantly from assessments under former guidance” (U.S.
EPA, 1996). The converse is also true. If compelling data are
forthcoming and assessments do not differ in any significant
manner from defaults, there will be little support for these
studies in the future. A partnership needs to exist where case
studies completed by agency personnel and those completed by
outside panels and groups would be jointly evaluated to distill
the lessons learned and to facilitate future mode of action based
assessments.
The two compounds evaluated by the ILSI HESI panel
provide interesting examples for this library of case studies.
With chloroform, there was both compelling evidence for a
non-linear mode of action and available data for developing a
TK model for use in quantitative dose-response evaluations.
DCA, however, lacks convincing evidence for a consensus
mode of action, although there is a body of evidence showing
various precursor responses in the liver. The panel’s judgment
was that this compound should be treated by non-linear doseresponse models, while retaining the flexibility to apply uncertainties in mode of action to influence the MOE calculations.
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Consistency of Mode of Action and Epidemiological Data
Since the publication of the panel’s report, the U.S. EPA has
published a NODA (notice of data availability) for several
disinfection byproducts (DBPs) including CHCl 3 (U.S. EPA,
1998) . In this document, EPA proposed a nonzero maximumcontaminant-level goal (MCLG) for CHCl 3. The basis of this
action was a thorough review of available literature and included reference to the conclusions of the ILSI HESI panel
report. This NODA and its recommendations generated significant controversy (U.S. EPA, 1998a,b). The controversy was
partially due to the epidemiological observation that some
populations exposed to water containing DBPs, which include
CHCl 3, appear to have increased risks of certain tumors, including bladder and colorectal cancer (Cantor et al., 1987;
Cragle et al., 1985; Young et al., 1987; McGeehin et al., 1993;
King and Marrett, 1996; Doyle et al., 1997; Freedman et al.,
1997; Hildesheim et al., 1998; Cantor et al., 1998). Since the
circulation of the initial NODA and public comment, EPA has
withdrawn the proposed non-zero MCLG, on the basis of
various procedural and risk management considerations (U.S.
EPA, 1998b).
While evaluation of the epidemiological data was not included in the scope of our deliberations, the debate engendered
by the NODA is an important controversy that will influence
the continued development of the new carcinogen risk-assessment guidelines. The panel recognizes that the dosimetry and
mode of action data for CHCl 3 from animal studies do need to
be considered in light of epidemiological studies. However, the
converse is also true— epidemiological inferences have to be
interpreted in light of compelling toxicity data from other
species. The conclusion from animal studies, completely justified and unanimously supported by the panel, is that toxicity
is a prerequisite to the induction of tumors by CHCl 3. In the
absence of high-dose, overt toxicity, CHCl 3 poses no significant carcinogenic risk to humans. The concentrations of CHCl 3
found in drinking water are very much below concentrations
associated with toxicity. Importantly, the target sites in animals
for CHCl 3 toxicity and carcinogenicity are not the sites where
excess risks have been found in the human populations exposed to water containing DBPs. In addition, no other mechanistic data indicate that intestinal or bladder tissues would be
targets in humans due to specific levels of enzymes or accumulation of toxic metabolites. Increased cancer incidence in
these populations may be related to factors including, but not
limited to, water disinfection by-products. However, the animal studies unanimously indicate that this increase is unlikely
to be associated directly with CHCl 3 exposures.
The toxicology of the various chemical classes of DBPs are
sufficiently distinct from each other that CHCl 3 cannot be
considered a good representative of all of these chemicals.
Some brominated THMs can cause tumors in the large intestine
in rats. Information gleaned from toxicity studies of all the
various THMs should be incorporated into the design of future
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epidemiological studies of human populations exposed to
DBPs. As a starting point, better interaction between toxicologists and epidemiologists in study design and reporting could
provide more emphasis on the consistencies and discrepancies
between animal studies and observations in human populations. This type of collaboration could aid in formulating
testable hypotheses regarding the role of specific DBPs in
human disease or the possibility that interactions occur among
the various DBPs. The panel’s evaluations clearly support the
recommendation of a nonzero MCLG for CHCl 3. However, the
panel did not evaluate other THMs and made no conclusions
regarding appropriate risk assessment approaches or exposure
limits for these compounds. For regulation of CHCl 3 alone, we
emphasize that non-linear extrapolation is appropriate and a
nonzero MCLG would be entirely in order.

SUMMARY

In this perspective, the ILSI HESI panel has reflected on its
experience in applying the proposed EPA guidelines for carcinogen risk assessment to CHCl 3 and DCA. The panel consisted of ten experts from diverse fields in toxicology and risk
assessment. The practical experience of several members in
risk assessment was particularly useful in our deliberations.
The flexibility of the guidelines concerning mode of action and
encouraging utilization of these data for dose response assessments is a marked improvement and a welcome change. These
guidelines serve as a sound template for incorporating stateof-the-art mode of action data into carcinogen risk assessments. Some points in the guidelines require further development, including more careful linking of dosimetry with the
biological mode of action. Factors influencing calculations of
the MOE for carcinogens are vaguely enumerated in the guidelines and are not closely tied to current practices in noncancer
risk assessment. Better coordination of these cancer guidelines
with practices for noncancer risk assessment should improve
the quantitative dose response assessments and MOE assessments for carcinogens. Expert panel efforts such as this one
will incrementally develop a case library to guide future cancer
risk assessments. The value of participation of a broadly based
collection of experts in these early assessments provides a
learning experience for the agency in conducting the assessments and for panel members in appreciating the breadth of
disciplines required to complete a contemporary cancer risk
assessment. It is hoped that the EPA itself might complete risk
assessments on specific compounds in the early stages of
guideline development in order to take an informed, proactive
stance on specific issues related to guideline implementation.
While some quantitative considerations remain to be clarified
in revision, the essential flexibility in assessing new scientific
data present in these guidelines should not be compromised.
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